Cytori Therapeutics Inc (NASDAQ:CYTX) has been assigned a $5.00 price objective by investment analysts at Maxim Group in a research note issued on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on CYTX. Zacks Investment Research upgraded Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research note on Tuesday, July 11th. B. Riley restated a “neutral” rating on shares of Cytori Therapeutics in a research note on Wednesday, August 16th. Finally, ValuEngine cut Cytori Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st.

Shares of Cytori Therapeutics (NASDAQ:CYTX) traded up 7.53% during trading on Thursday, reaching $0.50. The company’s stock had a trading volume of 3,050,513 shares. The firm’s 50-day moving average is $0.41 and its 200-day moving average is $0.76. The stock’s market capitalization is $17.36 million. Cytori Therapeutics has a 12-month low of $0.28 and a 12-month high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Cytori Therapeutics had a negative return on equity of 202.62% and a negative net margin of 450.34%. The firm had revenue of $0.90 million during the quarter, compared to analysts’ expectations of $2.23 million. During the same quarter in the previous year, the business earned ($0.43) earnings per share. The company’s revenue for the quarter was down 18.2% compared to the same quarter last year. Equities analysts expect that Cytori Therapeutics will post ($0.60) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Maxim Group Reiterates $5.00 Price Target for Cytori Therapeutics Inc (CYTX)” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/22/maxim-group-reiterates-5-00-price-target-for-cytori-therapeutics-inc-cytx.html.

Hedge funds have recently made changes to their positions in the stock. Sabby Management LLC raised its position in Cytori Therapeutics by 28.0% during the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after acquiring an additional 355,504 shares in the last quarter. Perkins Capital Management Inc. raised its position in Cytori Therapeutics by 99.0% during the second quarter. Perkins Capital Management Inc. now owns 874,896 shares of the biotechnology company’s stock valued at $962,000 after acquiring an additional 435,217 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Institutional investors own 11.82% of the company’s stock.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.